Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

ABSTRACT:

Background

A significant subset of prostate cancer (PC) patients with a castration-resistant form of the disease (CRPC) show primary resistance to androgen receptor (AR)-targeting drugs developed against CRPC. As one explanation could be the expression of constitutively active androgen receptor splice variants (AR-Vs), our current objectives were to study AR-Vs and other AR aberrations to better understand the emergence of CRPC.

Methods

We analysed specimens from different stages of prostate cancer by next-generation sequencing and immunohistochemistry.

Results

AR mutations and copy number variations were detected only in CRPC specimens. Genomic structural rearrangements of AR were observed in 5/30 metastatic CRPC patients, but they were not associated with expression

SUBMITTER: Kallio HML 

PROVIDER: S-EPMC6070921 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature